XNAS
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-14 | Q2 2026 | — | -2.40 | — | $0 | — | -2.16% | +8.33% | — |
| 2026-05-14 | Q1 2026 | — | -0.11 | — | $0 | — | +3.97% | +4.83% | +2.59% |
| 2026-03-30 | Q4 2025 |
| — |
| -0.12 |
| — |
| $0 |
| — |
| -2.08% |
| +8.40% |
| -15.16% |
| 2025-11-17 | Q3 2025 | — | -0.04 | — | $0 | — | — | — | — |
| 2025-09-09 | Q2 2025 | — | 0.00 | — | $0 | — | — | — | — |
Showing last 5 quarters.